Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has dosed the first patient in the pivotal Phase II study of the company’s novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of the company’s five drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key products of the company’s apoptosis-targeted pipeline Read More ›

SUZHOU, China, and ROCKVILLE, MD., Jan. 11, 2022 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Dr. Dajun Yang, the company’s Chairman and CEO, delivered a presentation at the virtually-held 40th Annual J.P. Morgan Healthcare Conference in the Read More ›

SUZHOU, China, and ROCKVILLE, MD., Dec. 14, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three clinical studies of the company’s novel drug candidate, olverembatinib, at the 63rd American Society Read More ›

SUZHOU, China, and ROCKVILLE, MD., Dec. 14, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from six studies of the company’s three novel drug candidates (olverembatinib, lisaftoclax [APG-2575], and pelcitoclax [APG-1252]) Read More ›

Ascentage Pharma (6855.HK) today announced that the Phase II pivotal study (the APG2575CC201 study) of the company’s novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) has been approved by the Center for Drug Evaluation (CDE) in China. isaftoclax, with objective response rate (ORR) as the Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has entered into a clinical collaboration with Clover Biopharmaceuticals, Ltd. (or “Clover”; Stock Code: 2197.HK) to evaluate Ascentage Pharma’s APG-1387, a second mitochondria-derived activator of caspase (SMAC)-mimetic/inhibitor of apoptosis proteins Read More ›

SUZHOU, China, and ROCKVILLE, MD, Nov. 30, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the appointment of Mr. Yiqing Chen as Chief Financial Officer (CFO), reporting directly to Dr. Dajun Yang, Chairman and Chief Executive Officer (CEO) of Ascentage Pharma. As a member of the company’s Read More ›

SUZHOU, China, and ROCKVILLE, MD., Nov.22, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC) has granted the company’s novel drug candidate, olverembatinib (HQP1351), an Orphan Designation for the treatment of chronic myeloid leukemia Read More ›